---
schema_version: "secwatch.filing_event.v1"
accession: "0001645666-25-000004"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:00:21.042771+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Kezar presents zetomipzomib safety update from PALIZADE Phase 2b lupus nephritis trial

## Summary
- KOL event hosted by William Blair covering zetomipzomib in autoimmune hepatitis and lupus nephritis.
- Safety update from PALIZADE Phase 2b trial (active lupus nephritis) disclosed at event; no specific data provided.
- No financial results, guidance changes, or regulatory decisions announced.
- Company undertakes no obligation to update the presentation materials.

## SEC filing metadata
- accession: 0001645666-25-000004
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000004/0001645666-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000164566625000004/kzr-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645666-25-000004
- JSON: https://secwatch.observer/filing/0001645666-25-000004.json
- Plain text: https://secwatch.observer/filing/0001645666-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.